Given the well-established role of the GLP-1 pathway in T2D management, CT-388 could potentially fit within the current standard of care in several ways: Weight Loss : CT-388 has demonstrated significant, rapid, and dose-proportional weight loss in the trial subjects, which is a key therapeutic goal in both obesity and T2D management
These are typically mild and include: Nausea/vomiting Digestive issues Abdominal discomfort Diarrhea or constipation Fatigue Heartburn Side effects of semaglutide typically decrease over time as your body adjusts to the medication, and we are mindful to prescribe dosage levels that minimize side effects
Skip the missed dose and continue with your regular scheduledont take extra to compensate
He said lighter, blue eyes could become even lighter over time
This includes potentially revising tax policies, investing in infrastructure and fostering an educated workforce
Regulates blood sugar By improving insulin sensitivity, Semaglutide helps prevent the energy crashes that trigger cravings